|Description||Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 by binding to the ATP-binding site.IC50 = 2μM. Exhibits antitumor and cytocidal activities (IC50~ 0.4 μM) by causing degradation of key oncogenic client proteins such as ErbB2 and cRaf1. Exhibits higher affinity and potency than geldanamycin.|
|Brife Description||Macbecin I is a Hsp90 inhibitor.|
|Appearance||Yellow lyophilised solid|
|Solubility||Soluble in DMSO|
|Storage||Desiccate at -20°C|
The methlate salt form of PF-04929113 that has potential antineoplastic activity targeting Hsp90. It could probably result in the proteasomal degradation of onc...
CCT018159 is a novel inhibitor of heat shock protein (Hsp) 90 with potential anticancer activity. CCT018159 inhibited human Hsp90beta with comparable potency to...
STA-1474 is a H2O soluble prodrug of ganetespib (formerly STA-9090). STA-1474 will metabolize to Ganetespib, which is a potent Hsp90 inhibitor previously shown ...
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.
NVP-BEP800 is a novel, fully synthetic Hsp90β inhibitor with IC50 of 58 nM, exhibits >70-fold selectivity against Hsp90 family members Grp94 and Trap-1.
Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds...
Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic a...
KF58333 is a novel derivative of radicicol, binds to the Hsp90 chaperone machinery, depletes p210Bcr-Abl and Raf-1 proteins followed by induction of erythroid d...
SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell prolife...
17-AAG is an orally bioavailable, small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activit...
Herbimycin A is an ansamycin antibiotic that acts as a Src family kinase inhibitor. Binds to the SH domain and inhibits the activity of p60v-src and p210BCR-ABL...
Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (Hsp90) with antiproliferative and antineoplastic activities.Retaspimycin binds to ...
SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...
PU H71 is a potent potent inhibitor of heat shock protein 90 (Hsp90) (IC50 = 51 nM in MDA-MB-468 cells), also inhibits cell growth in a range of breast cancer c...
An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhi...
Retaspimycin HCl(IPI504 HCl) is the hydrochloride salt of a small-molecule inhibitor of Hsp90 with antineoplastic and antiproliferative activities. Retaspimycin...
XL888 is an ATP-competitive inhibitor of Hsp90. Through this action, specific client proteins are degraded, leading to cell cycle arrest or apoptosis. XL888 is ...
PU-WS13 is a cell-permeable inhibitor of Grp94 (EC50 = 220 nM).It shows selectivity for Grp94 over the related Hsps Trap-1, Hsp90α, and Hsp90β. PU-WS13 blocks t...
Radester is a hybrid composed of radicicol's resorcinol and geldanamycin’s benzoquinone part structures and exhibits good cellular activity against MCF7 breast ...
Gedunin is a naturally occurring Hsp90 inhibitor. Induces Hsp90-dependent client protein degradation and displays antiproliferative activity in vitro (IC50 valu...